Cardiovascular Systems — Replidyne — Rodman & Renshaw NYC (November 2006)
24 slides from Cardiovascular Systems's conference presentation, Nov 6, 2006
Slide 1: Rodman & Renshaw NYC
Rodman & Renshaw NYC We are providing this information as of November 7, 2006 and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise. Peter Letendre - Chief Commercial Officer November 7,
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements about Replidyne, Inc. Our actual results could differ materially from those discussed due to a number of factors including, the success and timing of our pre-clinical studies and clinical trials; our ability to obtain a
Slide 3: Evergreen unmet medical need in anti-infectives
"Evergreen unmet medical need" due to eventually resistance to all antibiotics Resistance Opportunity created from big pharma's shift to other therapeutic areas Big Pharma A biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective produ
Slide 4: Replidyne Product Pipeline
Discovery Preclinical Phase 1 Phase II Phase III NDA Discovery Research C. difficile Program DNA Replication Inhibition Program Faropenem medoxomil Respiratory Tract and Skin Infections Bronchitis Study Acute Otitis Media Replidyne Product Pipeline REP8839 Treatment of skin and wound infections Prev
Slide 5: Replidyne key assets
Faropenem Medoxomil Replidyne key assets NDA filed - December '05; accepted February '06 Clinical trials in ABS, CAP, AECB, and uncomplicated skin infections FDA non-approvable letter - October '06 Changing FDA landscape Superiority trials & microbiologic evaluation recommended Safety database of 50
Slide 6: Faropenem background
Discovered by Suntory (now Daiichi Asubio) Prodrug form of faropenem with improved bioavailability 13 Phase III clinical trials completed by Bayer 5000 patients safely treated Licensed from Daiichi Asubio - March 2004 Faropenem background Faropenem Medoxomil
Slide 7: Faropenem - Timeline of events
Sinusitis Pneumonia Faropenem - Timeline of events Further discussions with FDA All non-inferiority studies Initiated superiority trial in AECB Forest partnership
Slide 8: Faropenem - FDA recommendations
Faropenem - FDA recommendations NDA submitted based on industry standard non- inferiority studies Scientific discussion: What data should be required to approve respiratory indications? Non-approvable letter recommending superiority studies and microbiologic evaluation Moving forward: FDA post-actio
Slide 9: Orapem's Promising Pediatric Opportunity
Beta-lactams endorsed by CDC and AAP guidelines as 1st and 2nd line therapy for key indications Orapem's Promising Pediatric Opportunity Taste of suspension is key driver of prescribing decision Branded competitive landscape expected favorable by estimated launch
Slide 10: Faropenem Partnership with Forest Laboratories
Forest Laboratories partnership Indicated continued support of faropenem program To participate in discussions with FDA Successful track record of commercialization in mature markets Financial Terms Up to $250 million in license fees and milestones $60 million received to date Significant royalty on
Slide 11: Oral antibiotics - Class distinctions
Oral Penems Oral antibiotics - Class distinctions Beta-Lactams Penicillins Cephalosporins Macrolides/ Ketolides Cipro Levaquin Avelox Factive Quinolones Tequin
Slide 12: Oral antibiotics - Market potential
Oral Antibiotic Market Sales Dollars Oral Antibiotic Market Total Prescriptions Oral antibiotics - Market potential Source: 2005 IMS NPA Audit 1999 2000 2001 2002 2003 2004 2005 Oral Antibiotic Market 274.855 273.396 275.29 271.499 269.873 252.181 274.793 Millions 1999 2000 2001 2002 2003 2004 2005
Slide 13: Beta-Lactams: Dominating Oral Antibiotic Markets
Pediatric Market Share Adult Market Share Beta-Lactams: Dominating Oral Antibiotic Markets Macrolides/ Ketolides 24% Quinolones 17% Other Antibiotics 16% Beta-Lactams 43% 2005 220 Million Prescriptions Total Market = $7.0 Billion 2005 50 Million Prescriptions Total Market = $1.5 Billion Macrolides 2
Slide 14: REP8839
REP8839 Selective inhibitor of methionyl tRNA synthetase Target indications: Treatment of skin infections Prevention of S. aureus infections (including MRSA) in hospital Program acquired from GSK A need for an improved topical antibiotic
Slide 15: REP8839 Development Status
REP8839 Being developed alone and as a combination of REP8839 and Mupirocin (Bactroban(r)) Mupirocin is the leading topical antibiotic Resistance to Mupirocin increasing Each agent has a distinctive mechanism of action (but both are tRNA synthetase inhibitors) Combination may prevent emergence of dr
Slide 16: REP8839 combination product reduced resistance emergence
Mupirocin (1 µg/ml) REP8839 + Mupirocin (1 µg/ml) REP8839 (1 µg/ml) Combination product Dramatically reduced resistance emergence S. aureus ATCC29213 (MSSA) 53 22 0 S. aureus ATCC43300 (MRSA) 65 28 0 S. aureus LZ10 (MRSA) 12 2 0 S. aureus NRS103 (MRSA) 40 24 0 S. aureus 1079077 (MRSA) 99 29 0 S. epi
Slide 17: Discovery programs
Bacterial DNA replication is an essential process; new mechanism-of-action antibiotic High-throughput assays - Target the DNA replication complexes from multiple bacteria Currently at lead optimization stage DNA Replication Inhibitors program Increasing public health threat in elderly patients Ident
Slide 18: Intellectual property
Intellectual property Faropenem Composition of matter Methods of manufacture Expiration date November 15, 2015 Patent term extension available under Hatch-Waxman 2 U.S. patents licensed from Daiichi Asubio for faropenem Composition of matter, combination therapy, targets, etc. Patent expirations ran
Slide 19: Business development strategy
Replidyne Business development strategy In-licensing Novel anti-bacterials Other promising anti-infectives Marketed product opportunities Pediatric products - to complement faropenem oral suspension Faropenem partnering - Europe Complementary Approaches
Slide 20: Proven management team
Prior Experience Proven management team [photo] Kenneth Collins Synergen Neurogenetics President & CEO Roger Echols, M.D. BMS Bayer Chief Medical Officer Nebojsa Janjic, Ph.D. NeXstar Scripps Chief Scientific Officer Prior Experience Peter Letendre, Pharm.D. Abbott GSK Chief Commercial Officer Don M
Slide 21: Financial summary
$134 million Cash balance at Sept 30 Financial summary Through September 30, 2006 $30 million (for 9 month period) Burn rate (3Q 2006) Financial highlights Partner contributes funding for faropenem related R&D and sales and marketing
Slide 22: Near-Term Milestones
2007 2006 Faropenem Adult ABS, CAP, uSSSI AECB Placebo Phase III Results Pediatric Pediatric Phase II Data Initiate Pediatric Phase III REP8839 Submit IND Complete Phase I Clinical Studies Near-Term Milestones FDA post-action PIII development 2H 2007 1H 2007 2H 2007 Mid 2006 Early 2007
Slide 23: Replidyne - Key assets
Novel antibiotic pipeline addressing growing problem of Staph infections, including MRSA Experienced team with proven clinical business development and commercial track record Replidyne - Key assets Faropenem - Meet with FDA & define next steps
Slide 24: Rodman & Renshaw NYC
Rodman & Renshaw NYC We are providing this information as of November 7, 2006 and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise. Peter Letendre - Chief Commercial Officer November 7,